ABLYNX ANNOUNCES WARRANT EXERCISE


REGULATED INFORMATION

GHENT, Belgium, June 5, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 83,000 common shares have been issued by the Company in exchange for €410,955.00 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 54,407,572 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t:   +44 203 709 5700
e: ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1926521/691368.pdf

HUG#1926521